Use of peripheral blood stem cells to accelerate hemopoietic recovery following autologous bone marrow transplantation.
Twenty-one patients with high risk non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) underwent autologous bone marrow transplantation (ABMT). Nine out of 21 patients received in addition to bone marrow (BM) cells also peripheral blood (PB) cells collected by leucapheresis performed in the recovery phase after high-doses of either cyclophosphamide or etoposide (7 patients), or after ara-C (2 patient). All patients receiving BM + PB cells had ABMT as salvage therapy following extensive relapse or progression of their disease. The addition of PB cells to BM cells allowed a significantly faster recovery after ABMT. Median time to reach WBC greater than 1,000/microL was 14 days versus 20.5 days for patients receiving BM only. Furthermore, a reduced requirement of supportive care and a shorter period of isolation was observed. These results confirm that PB cells combined with BM cells allow a prompt hematopoietic reconstitution after myeloablation. In addition, the data demonstrate the efficacy of PB cells collected after various cytotoxic drugs, even in patients previously exposed to cytoreductive regimens.
Tarella
C
C
Divisione Universitaria di Ematologia, Ospedale Molinette Torino, Italy.
Gavarotti
P
P
Caracciolo
D
D
Locatelli
F
F
Falda
M
M
Paolino
F
F
Lovisone
E
E
Sormano
E
E
Tassi
V
V
Urgesi
A
A
D000293:Adolescent; D000328:Adult; D001804:Blood Transfusion, Autologous / Q000379:methods*; D016026:Bone Marrow Transplantation; D005260:Female; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors